5734-66-7

Basic information

• Product Name: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)
• Synonyms: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI);2-AMINO-6-ETHYL-4(1H)-PYRIMIDINONE;4(1H)-Pyrimidinone, 2-amino-6-ethyl-;4(3H)-Pyrimidinone,2-amino-6-ethyl-;2-Amino-4-hydroxy-6-ethylpyrimidine;6-Ethylisocytosine;2-diazenyl-6-ethylpyrimidin-4-ol;2-Amino-6-ethylpyrimidin-4-ol
• CAS NO: 5734-66-7
• Molecular Formula: C₆H₉N₃O
• Molecular Weight: 139.15516
• Product Categories: PYRIMIDINE;Drug Intermediates
• Mol File: 5734-66-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 243-245 °C (decomp)
• Boiling Point: 265℃
• Flash Point: 114℃
• Appearance: /
• Density: 1.35
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.98±0.50(Predicted)
• CAS DataBase Reference: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)(5734-66-7)
• EPA Substance Registry System: 4(1H)-Pyrimidinone, 2-amino-6-ethyl- (9CI)(5734-66-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5734-66-7(Hazardous Substances Data)

Usage

Uses

2,6-Bis(2-pyridyl)-4(1H)-pyridone?belongs to pyrimidine derivatives and can be used as pharmaceutical intermediates.

InChI:InChI=1/C6H9N3O/c1-2-4-3-5(10)9-6(7)8-4/h3H,2H2,1H3,(H3,7,8,9,10)

Upstream product

• 593-85-1 diguanidine carbonate 
• 4949-44-4 ethyl propanoylacetate 
• 50-01-1 guanidine hydrochloride 
• 64-17-5 ethanol 
• 30414-53-0 methyl propanoyl acetate 

Downstream Products

• 15043-03-5 6-ethylpyrimidine-2,4(1H,3H)-dione 
• 5734-67-8 2-amino-4-chloro-6-ethylpyrimidine 
• 514854-12-7 2,4-diamino-6-ethylpyrimidine 
• 58-14-0 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine 
• 514854-15-0 2-amino-6-ethyl-4-methoxypyrimidine 
• 514854-13-8 2,4-diamino-6-ethyl-5-iodopyrimidine 
• 1193-85-7 4-ethylpyrimidin-2-amine 
• 1393883-07-2 C₂₁H₁₉FN₆ 

Relevant articles and documents

Direct synthesis of 5- and 6-substituted 2-aminopyrimidines as potential non-natural nucleobase analogues

A series of 2-aminopyrimidine derivatives, substituted at 5- and 6-positions, were synthesized. The reaction was carried out in a single step by treatment of the corresponding β-ketoester or β-aldehydoester with guanidine hydrochloride in the presence of K2CO3, in a microwave-assisted method without the requirement of solvent. A unique 1:1 co-crystal structure was obtained which shows that a 6-phenyl-2- aminopyrimidinone forms a strong nucleobase-pair with cytosine, involving three hydrogen bonds. The base-pair was found to be as strong as that of natural guanine:cytosine (G:C), signifying the potential application of the synthesized derivatives. Additionally, we also report a second co-crystal involving 5-isopropyl-6-methyl-2-aminopyrimidinone and cytosine in a 1:1 ratio, which also shows strong base-pairing properties. the Partner Organisations 2014.

Quinolinyl pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents

NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

Pyrimidine Derivatives As HSP90 Inhibitors

The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or